Here are the Form 4 insider transactions from Avenue Therapeutics Inc (ATXI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ATXI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATXI filings page.
Avenue Therapeutics, Inc. reported an insider stock award linked to preferred stock dividends. A reporting person who is both a director and a 10% owner received 111,209 shares of common stock on 01/02/2026 at a price of $0. These shares were granted as the 2025 annual dividend on the holder’s Class A Preferred Stock, which is entitled to a 2.5% annual dividend based on Avenue’s fully diluted outstanding capitalization on December 31. After this grant, the reporting person beneficially owned 439,733 shares of Avenue Therapeutics common stock in direct ownership.